Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.

Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ.

J Clin Endocrinol Metab. 2011 Nov;96(11):3493-501. doi: 10.1210/jc.2011-0501. Epub 2011 Aug 24.

2.

Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study.

Wehr E, Pieber TR, Obermayer-Pietsch B.

J Endocrinol Invest. 2011 Nov;34(10):757-63. doi: 10.3275/7748. Epub 2011 May 24.

PMID:
21613813
3.

PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis.

de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM.

Hum Reprod Update. 2011 Jul-Aug;17(4):495-500. doi: 10.1093/humupd/dmr001. Epub 2011 Feb 18. Review.

PMID:
21335359
4.

Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.

Yasmin E, Glanville J, Barth J, Balen AH.

Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):67-71. doi: 10.1016/j.ejogrb.2010.12.041. Epub 2011 Feb 1.

PMID:
21277073
5.

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Escobar-Morreale HF, Luque-Ramírez M, González F.

Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2. doi: 10.1016/j.fertnstert.2010.11.036. Epub 2010 Dec 17. Review.

6.

Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS.

Fertil Steril. 2011 Apr;95(5):1849-52. doi: 10.1016/j.fertnstert.2010.11.040. Epub 2010 Dec 8.

7.

Metformin in polycystic ovary syndrome.

Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C.

Ann N Y Acad Sci. 2010 Sep;1205:192-8. doi: 10.1111/j.1749-6632.2010.05679.x. Review.

PMID:
20840272
8.

Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.

Hanjalic-Beck A, Gabriel B, Schaefer W, Zahradnik HP, Schories M, Tempfer C, Keck C, Denschlag D.

Gynecol Endocrinol. 2010 Sep;26(9):690-7. doi: 10.3109/09513591003686379.

PMID:
20626240
9.

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.

Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA.

J Clin Endocrinol Metab. 2010 May;95(5):2038-49. doi: 10.1210/jc.2009-2724. Epub 2010 Apr 7. Review.

PMID:
20375205
10.

Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome.

Hadžiomerović-Pekić D, Wildt L, Weiss JM, Moeller K, Mattle V, Seeber BE.

Fertil Steril. 2010 Nov;94(6):2385-8. doi: 10.1016/j.fertnstert.2010.02.041. Epub 2010 Mar 31.

PMID:
20356587
11.

Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.

Kaya C, Pabuccu R, Cengiz SD, Dünder I.

Exp Clin Endocrinol Diabetes. 2010 Mar;118(3):161-6. doi: 10.1055/s-0029-1220770. Epub 2010 Feb 9.

PMID:
20146169
12.

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003053. doi: 10.1002/14651858.CD003053.pub4. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD003053.

PMID:
20091537
13.

The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome.

Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, Tuncel E, Erturk E, Imamoglu S.

J Endocrinol Invest. 2010 Apr;33(4):234-8. doi: 10.3275/6560. Epub 2009 Oct 9.

PMID:
19820295
14.

Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B.

Eur J Endocrinol. 2009 Oct;161(4):575-82. doi: 10.1530/EJE-09-0432. Epub 2009 Jul 23.

15.

Vitamin D: emerging new roles in insulin sensitivity.

Teegarden D, Donkin SS.

Nutr Res Rev. 2009 Jun;22(1):82-92. doi: 10.1017/S0954422409389301. Review.

PMID:
19555519
16.

Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome.

Diamanti-Kandarakis E, Piouka A, Livadas S, Piperi C, Katsikis I, Papavassiliou AG, Panidis D.

Eur J Endocrinol. 2009 May;160(5):847-53. doi: 10.1530/EJE-08-0510. Epub 2009 Feb 10.

17.

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.

Palomba S, Falbo A, Zullo F, Orio F Jr.

Endocr Rev. 2009 Feb;30(1):1-50. doi: 10.1210/er.2008-0030. Epub 2008 Dec 4. Review.

PMID:
19056992
18.

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR.

J Clin Endocrinol Metab. 2009 Feb;94(2):469-76. doi: 10.1210/jc.2008-1133. Epub 2008 Nov 4.

19.

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL.

J Clin Endocrinol Metab. 2009 Jan;94(1):103-8. doi: 10.1210/jc.2008-1750. Epub 2008 Oct 21.

PMID:
18940877
20.

Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome.

Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG.

Fertil Steril. 2009 Sep;92(3):1053-8. doi: 10.1016/j.fertnstert.2008.07.1757. Epub 2008 Oct 18.

PMID:
18930208

Supplemental Content

Support Center